San Francisco, September 9th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolling and Recruiting in Global Centers
San Francisco, June 19, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in multiple European and US centers.
Read MoreFirst Closings of Series B Financing Round
San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases, announced the first closings of its Series B financing round.
Read MoreRecardio presented at the Cell & Gene Therapy Conference in New York
San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.
Read MoreRecardio at J.P. Morgan Conference 2019
San Francisco, January 07, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, today announced that it is participating in the 37thAnnual J.P. Morgan Healthcare Conference on January 7thin San Francisco.
Read More